Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18 to 50 years~* Able and willing (in the Investigator's opinion) to comply with all study requirements~* Willing to allow the investigators to discuss the volunteer's medical history with their general practitioner (GP)~* For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of screening and vaccination~* Agreement to refrain from blood donation during the course of the study~* Provide written informed consent~Exclusion Criteria:~* Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period~* Prior receipt of an investigational Ebola or Marburg vaccine, a chimpanzee adenovirus vectored vaccine or any other investigational vaccine likely to impact on interpretation of the trial data~* Receipt of any live, attenuated vaccine within 28 days prior to enrolment~* Receipt of any subunit or killed vaccine within 14 days prior to enrolment~* Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate~* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, (e.g. egg products) including urticaria, respiratory difficulty or abdominal pain~* Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.~* Any history of anaphylaxis in reaction to vaccination~* Pregnancy, lactation or willingness/intention to become pregnant during the study~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)~* History of serious psychiatric condition~* Poorly controlled asthma or thyroid disease~* Seizure in the past 3 years or treatment for seizure disorder in the past 3 years~* Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venepuncture~* Any other serious chronic illness requiring hospital specialist supervision~* Current anti-tuberculosis prophylaxis or therapy~* Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week~* Suspected or known injecting drug abuse in the 5 years preceding enrolment~* Seropositive for hepatitis B surface antigen (HBsAg)~* Seropositive for hepatitis C virus (antibodies to HCV)~* Travel to a Ebola or Marburg endemic region during the study period or within the previous six months~* Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis (see Appendix A and Appendix B)~* Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data~* Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly
- Group 1b (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly, followed by 4.4x10\^8 TCID50s MVA-BN® Filo
- Group 1c (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 1 x 10\^10 vp intramuscularly, followed by 2.2x10\^8 TCID50s MVA-BN® Filo
- Group 2 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly
- Group 2b (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly, followed by 4.4x10\^8 TCID50s MVA-BN® Filo
- Group 2c (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly, followed by 2.2x10\^8 TCID50s MVA-BN® Filo
- Group 3 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 5 x 10\^10 vp intramuscularly
- Group 3b (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 5 x 10\^10 vp intramuscularly, followed by 4.4x10\^8 TCID50s MVA-BN® Filo
- Group 3c (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 5 x 10\^10 vp intramuscularly, followed by 2.2x10\^8 TCID50s MVA-BN® Filo
- Group 4 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 2.2 x 10\^8 TCID50s MVA-BN® Filo at day 7
- Group 5 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 2.2 x 10\^8 TCID50s MVA-BN® Filo at day 14
- Group 6 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 4.4 x 10\^7 TCID50s MVA-BN® Filo at day 7
- Group 7 (Type: EXPERIMENTAL): Single dose of cAd3-EBO Z at 2.5 x 10\^10 vp intramuscularly at day 0, followed by 4.4 x 10\^7 TCID50s MVA-BN® Filo at day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete